Sarepta gains ex-European license to Lysogene's LYS-SAF302 MPS IIIA gene therapy candidate; LYS-SAF302 License Agreement Terminated
Sarepta Therapeutics Inc. licensed exclusive worldwide commercialization (except in Europe) and manufacturing rights to Lysogene's LYS-SAF302 gene therapy candidate for the lysosomal storage disorder mucopolysaccharidosis type IIIA (MPS IIIA; also known as Sanfilippo A syndrome).
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.